RXDX - Prometheus Biosciences GAAP EPS of -$0.90 beats by $0.01 revenue of $0.97M beats by $0.39M
- Prometheus Biosciences press release ( NASDAQ: RXDX ): Q3 GAAP EPS of -$0.90 beats by $0.01 .
- Revenue of $0.97M (-4.0% Y/Y) beats by $0.39M .
- As of September 30, 2022, Prometheus had cash, cash equivalents and short-term investments of $260.2 million, compared to $257.3 million at the end of Q4 2021.
For further details see:
Prometheus Biosciences GAAP EPS of -$0.90 beats by $0.01, revenue of $0.97M beats by $0.39M